Injury guide
Ask your care team about the exact ovarian cancer diagnosis and treatment. Powder studies have different findings and limits.
Updated Oct 4, 202619 sources
See If You Qualify
Free · No obligation · About 2 minutes
Updated Oct 4, 202619 sources
This may apply to you if
These are cited sources. Their inclusion does not imply that they endorse People’s Justice or reviewed this page.
Katie M. O’Brien · Epidemiology Branch, National Institute of Environmental Health Sciences · First-listed author of the 2024 quantitative bias analysis
Finding: The 2024 study supports a positive association between reported genital talc use and ovarian cancer after the bias corrections examined. It does not pinpoint a specific cause or mechanism.
O’Brien et al.: 2024 intimate-care-products quantitative bias analysis (opens in a new tab) · May 15, 2024 · Checked Oct 3, 2026
NIEHS, with collaborating US cohort investigators · JAMA · 2020
Read the source: 2020 pooled genital-powder and ovarian-cancer study (opens in a new tab) · Checked Oct 3, 2026
NIEHS, with collaborating cancer and epidemiology investigators · Journal of Clinical Oncology · 2024
Read the source: 2024 Sister Study quantitative bias analysis (opens in a new tab) · Checked Oct 3, 2026
The process
You answer a few questions
About two minutes. Nothing is sent until you agree on the last step and press submit.
A lawyer looks at it
A lawyer at the firm reads your answers and checks them against the current case criteria.
The firm decides and gets in touch
If the firm takes your case, you get the terms in writing to read before you sign. You can always say no.
Ask your care team about the exact ovarian cancer diagnosis and treatment. Powder studies have different findings and limits. They do not establish that talc caused one person’s cancer.
They concern cancer of the ovary, not every cancer near the pelvis. Ask the care team for the exact diagnosis and where it began.
The NCI guide describes epithelial cancer starting in tissue covering the ovary. Its related care discussion includes fallopian-tube and primary peritoneal cancers. That clinical grouping is not proof that a legal program accepts all three.
Bloating, belly or pelvic pain and trouble eating can be signs. They can also have other causes. Get persistent or worsening symptoms checked.
Feeling full quickly does not diagnose ovarian cancer. Describe what changed and how long it has lasted. Do not wait for a product record or claim conversation before discussing a continuing health concern.
The care team uses clinical tests and checks tissue when needed. Ask what the diagnosis and stage mean for your care choices.
The patient guide describes examinations, imaging and laboratory tests, with biopsy tissue checked for cancer. A test result alone is not a product-cause finding. Care depends on the actual cancer type, extent and health factors.
Their results differ. The 2020 pooled study found no clear link overall. The 2024 bias-adjusted analysis found positive links under its assumptions.
The earlier analysis included 252,745 women with complete covariates; it could miss a small increase. The later eligible group was 49,806 before cancer-specific and model exclusions. It overlaps a prior cohort and depends on recall assumptions, so neither proves personal cause.
Ask a lawyer to check the cancer, powder history and proof. A hazard label or report about experts does not decide your own claim.
IARC classed talc as probably able to cause cancer but noted limits in human evidence. The January 2026 ovarian expert report made recommendations about testimony, not a final injury payment or ruling for every patient.
Keep tissue and care reports with the powder-use history you recall. Request missing copies and ask a lawyer to check your time limit.
As a preparation step, mark the dates and locations of diagnosis and product use, including uncertainty. Covered health-record access has exceptions. A study publication or court-report date does not set your filing cutoff.
Limited but consistent evidence in humans from epidemiological studies showing increased ovarian cancer risk with perineal talc use across multiple study designs and populations
Consistent positive association between perineal talc use and ovarian cancer risk, with hazard ratios typically ranging from 1.20 to 1.40
Women who used talcum powder for perineal hygiene had an odds ratio of 1.92 for ovarian cancer compared to non-users
The review is free and private. Asking for it doesn’t commit you to anything.
Register your interestThe evidence linking perineal talcum powder use to ovarian cancer is substantial and has been accumulating for over four decades. The 1982 Cramer et al. study found an odds ratio of 1.92, and subsequent studies — including large prospective cohort studies like the Harvard Nurses’ Health Study — have consistently confirmed a positive association with hazard ratios typically ranging from 1.20 to 1.40. The IARC upgraded talc to Group 2A ("probably carcinogenic") in July 2024 based on the totality of epidemiological, animal, and mechanistic evidence. Talc particles have been found embedded in ovarian tumors, confirming the migration pathway. The evidence is strong enough that juries across the country have returned billions in verdicts, and J&J discontinued talc-based Baby Powder.
Epidemiological studies show a dose-response relationship — the risk of ovarian cancer increases with the frequency and duration of perineal talc use. Women who used talcum powder daily for decades have the highest risk and the strongest claims. However, even less frequent use has been associated with elevated risk in multiple studies. There is no established "safe" level of perineal talc use. The IARC’s classification of talc as Group 2A applies to all perineal talc use, not just heavy use. If you used Baby Powder or other talc products for perineal hygiene at any frequency and were diagnosed with ovarian cancer, you should consult an attorney to evaluate your potential claim.
All major histological subtypes of ovarian cancer have been linked to perineal talc use in epidemiological studies, including serous, endometrioid, clear cell, and mucinous carcinomas. The strongest association has been demonstrated for serous ovarian cancer, which is the most common subtype (accounting for approximately 70% of ovarian cancers) and the most lethal. The IARC’s evaluation did not limit its Group 2A classification to any specific subtype. If you were diagnosed with any type of epithelial ovarian cancer after using talcum powder for perineal hygiene, you may have a viable claim regardless of the specific histological subtype.
Checked against 17 primary sources by People's Justice editors · Updated
How we make moneyPeople's Justice research team · Updated Oct 4, 2026